Should I Invest in Valeant? Valeant Pharmaceuticals (VRX) reported its earnings where both earnings and revenue missed analysts estimate. The year 2015 has been a terrible year for $VRX. The company had also been under fire over its accounting practices and drug pricing strategy. With change in management, investors gaze were fixed on this earnings. This was the first earnings under the new CEO Joseph Papa. Now the big question is whether or not Papa has the ability to turn things right.